22UA:FRA
BioNTech SE
€ 80.25
arrow_upward
+0.82%(+0.65) Siku 1
16 Okt, 12:42:30 GMT +2 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 22UA...
Fungua
€ 80.15
Juu
€ 81.25
Chini
€ 80.15
Mtaji wa soko
22.66B
Wastani wa kiasi cha mauzo
elfu 1.43
Kiasi cha mauzo ya hisa
203.00
Juu kwa wiki 52
€ 105.50
Chini kwa wiki 52
€ 68.00
Idadi ya wafanyakazi
elfu 8
Fungua
€ 80.15
Juu
€ 81.25
Chini
€ 80.15
Mtaji wa soko
22.66B
Wastani wa kiasi cha mauzo
elfu 1.43
Kiasi cha mauzo ya hisa
203.00
Juu kwa wiki 52
€ 105.50
Chini kwa wiki 52
€ 68.00
Idadi ya wafanyakazi
elfu 8
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 20 zilizopita
Canaccord cuts target for BioNTech stock to USD 132.00
Pluang
·
siku 1 iliyopita
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
siku 2 zilizopita
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TipRanks
·
siku 2 zilizopita
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
Wasifu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Kuhusu BioNTech SE